Does the media favor PACB or NAUT?

In the previous week, Pacific Biosciences of California and Pacific Biosciences of California both had 2 articles in the media. Pacific Biosciences of California's average media sentiment score of 0.39 beat Nautilus Biotechnology's score of 0.00 indicating that Pacific Biosciences of California is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NAUT or SLP?

In the previous week, Simulations Plus had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 3 mentions for Simulations Plus and 2 mentions for Nautilus Biotechnology. Simulations Plus' average media sentiment score of 1.23 beat Nautilus Biotechnology's score of 0.00 indicating that Simulations Plus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Simulations Plus 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CDXS or NAUT?

In the previous week, Codexis and Codexis both had 2 articles in the media. Codexis' average media sentiment score of 1.74 beat Nautilus Biotechnology's score of 0.00 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nautilus Biotechnology (NAUT) Competitors

$0.90 -0.01 (-1.59%)

As of 04:00 PM Eastern

Compare

NAUT vs. PACB, TKNO, SLP, LAB, and CDXS

Should you buy Nautilus Biotechnology stock or one of its competitors? Nautilus Biotechnology's main competitors and comparable companies include Pacific Biosciences of California (PACB), Alpha Teknova (TKNO), Simulations Plus (SLP), Standard BioTools (LAB), and Codexis (CDXS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Pacific Biosciences of California (NASDAQ:PACB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

50.7% of Nautilus Biotechnology shares are owned by institutional investors. 3.7% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pacific Biosciences of California has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

In the previous week, Pacific Biosciences of California and Pacific Biosciences of California both had 2 articles in the media. Pacific Biosciences of California's average media sentiment score of 0.39 beat Nautilus Biotechnology's score of 0.00 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nautilus Biotechnology has a net margin of 0.00% compared to Pacific Biosciences of California's net margin of -82.49%. Nautilus Biotechnology's return on equity of -37.58% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Nautilus Biotechnology has lower revenue, but higher earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	2.62	-$546.38M	-$0.43	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

Pacific Biosciences of California presently has a consensus target price of $1.83, indicating a potential upside of 35.80%. Nautilus Biotechnology has a consensus target price of $4.00, indicating a potential upside of 342.04%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Nautilus Biotechnology beats Pacific Biosciences of California on 7 of the 12 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Alpha Teknova?

Nautilus Biotechnology (NASDAQ:NAUT) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Nautilus Biotechnology had 2 more articles in the media than Alpha Teknova. MarketBeat recorded 2 mentions for Nautilus Biotechnology and 0 mentions for Alpha Teknova. Nautilus Biotechnology's average media sentiment score of 0.00 equaled Alpha Teknova'saverage media sentiment score.

Company	Overall Sentiment
Nautilus Biotechnology	Neutral
Alpha Teknova	Neutral

Nautilus Biotechnology has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Nautilus Biotechnology has a net margin of 0.00% compared to Alpha Teknova's net margin of -38.37%. Alpha Teknova's return on equity of -24.94% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Alpha Teknova	-38.37%	-24.94%	-16.53%

Alpha Teknova has higher revenue and earnings than Nautilus Biotechnology. Alpha Teknova is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Alpha Teknova	$40.52M	9.16	-$17.26M	-$0.31	N/A

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 13.2% of Alpha Teknova shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nautilus Biotechnology currently has a consensus target price of $4.00, indicating a potential upside of 342.04%. Alpha Teknova has a consensus target price of $7.50, indicating a potential upside of 8.38%. Given Nautilus Biotechnology's higher probable upside, research analysts clearly believe Nautilus Biotechnology is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Alpha Teknova beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Simulations Plus?

Nautilus Biotechnology (NASDAQ:NAUT) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Nautilus Biotechnology currently has a consensus price target of $4.00, suggesting a potential upside of 342.04%. Simulations Plus has a consensus price target of $17.25, suggesting a potential downside of 6.40%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, research analysts plainly believe Nautilus Biotechnology is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

Nautilus Biotechnology has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

In the previous week, Simulations Plus had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 3 mentions for Simulations Plus and 2 mentions for Nautilus Biotechnology. Simulations Plus' average media sentiment score of 1.23 beat Nautilus Biotechnology's score of 0.00 indicating that Simulations Plus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Simulations Plus	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nautilus Biotechnology has higher earnings, but lower revenue than Simulations Plus. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Simulations Plus	$79.18M	4.71	-$64.72M	$0.40	46.08

Simulations Plus has a net margin of 9.88% compared to Nautilus Biotechnology's net margin of 0.00%. Simulations Plus' return on equity of 13.50% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Simulations Plus	9.88%	13.50%	12.45%

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 78.1% of Simulations Plus shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by company insiders. Comparatively, 19.1% of Simulations Plus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Simulations Plus beats Nautilus Biotechnology on 9 of the 14 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Standard BioTools?

Nautilus Biotechnology (NASDAQ:NAUT) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Nautilus Biotechnology has higher earnings, but lower revenue than Standard BioTools. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Standard BioTools	$85.33M	3.15	-$74.90M	$0.22	3.12

Nautilus Biotechnology currently has a consensus price target of $4.00, suggesting a potential upside of 342.04%. Standard BioTools has a consensus price target of $1.35, suggesting a potential upside of 96.94%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, research analysts plainly believe Nautilus Biotechnology is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Nautilus Biotechnology has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

In the previous week, Nautilus Biotechnology had 2 more articles in the media than Standard BioTools. MarketBeat recorded 2 mentions for Nautilus Biotechnology and 0 mentions for Standard BioTools. Nautilus Biotechnology's average media sentiment score of 0.00 equaled Standard BioTools'average media sentiment score.

Company	Overall Sentiment
Nautilus Biotechnology	Neutral
Standard BioTools	Neutral

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by company insiders. Comparatively, 26.8% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Standard BioTools has a net margin of 100.36% compared to Nautilus Biotechnology's net margin of 0.00%. Standard BioTools' return on equity of -7.57% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Standard BioTools	100.36%	-7.57%	-6.14%

Summary

Standard BioTools beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Codexis?

Codexis (NASDAQ:CDXS) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Nautilus Biotechnology has a net margin of 0.00% compared to Codexis' net margin of -39.55%. Nautilus Biotechnology's return on equity of -37.58% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Codexis has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Codexis has higher revenue and earnings than Nautilus Biotechnology. Codexis is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.27	-$43.97M	-$0.34	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

Codexis currently has a consensus target price of $6.50, suggesting a potential upside of 345.21%. Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 342.04%. Given Codexis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Codexis is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

78.5% of Codexis shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Codexis and Codexis both had 2 articles in the media. Codexis' average media sentiment score of 1.74 beat Nautilus Biotechnology's score of 0.00 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Codexis beats Nautilus Biotechnology on 10 of the 13 factors compared between the two stocks.

Get Nautilus Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAUT vs. The Competition

Export

Metric	Nautilus Biotechnology	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$117.01M	$9.93B	$7.17B	$12.88B
Dividend Yield	N/A	1.46%	2.53%	8.57%
P/E Ratio	N/A	65.01	272.99	25.40
Price / Sales	N/A	111.65	612.73	97.00
Price / Cash	N/A	26.86	77.82	52.27
Price / Book	0.88	35.98	12.85	6.17
Net Income	-$59M	$56.67B	$3.47B	$349.50M
7 Day Performance	2.17%	-0.83%	1.24%	-0.05%
1 Month Performance	-8.16%	4.54%	5.81%	0.80%
1 Year Performance	38.83%	26.48%	25.75%	15.62%

Nautilus Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAUT Nautilus Biotechnology	1.8937 of 5 stars	$0.90 -1.6%	$4.00 +342.0%	+43.9%	$117.01M	N/A	N/A	130	News Coverage
PACB Pacific Biosciences of California	1.764 of 5 stars	$1.52 +18.8%	$1.83 +20.6%	+3.2%	$397.86M	$160.01M	N/A	730	Gap Up High Trading Volume
TKNO Alpha Teknova	1.3633 of 5 stars	$7.46 +1.6%	$7.50 +0.5%	+70.4%	$393.53M	$40.52M	N/A	240
SLP Simulations Plus	1.352 of 5 stars	$18.39 -0.1%	$17.25 -6.2%	+28.1%	$372.14M	$79.18M	45.98	160	Positive News
LAB Standard BioTools	3.0579 of 5 stars	$0.65 flat	$1.35 +107.7%	-47.8%	$255.18M	$85.33M	2.95	620

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAUT) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. PACB, TKNO, SLP, LAB, and CDXS

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Summary

How does Nautilus Biotechnology compare to Alpha Teknova?

Summary

How does Nautilus Biotechnology compare to Simulations Plus?

Summary

How does Nautilus Biotechnology compare to Standard BioTools?

Summary

How does Nautilus Biotechnology compare to Codexis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. PACB, TKNO, SLP, LAB, and CDXS

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Do insiders & institutionals have more ownership in PACB or NAUT?

Which has more risk & volatility, PACB or NAUT?

Does the media favor PACB or NAUT?

Is PACB or NAUT more profitable?

Which has higher valuation and earnings, PACB or NAUT?

Do analysts rate PACB or NAUT?

Summary

How does Nautilus Biotechnology compare to Alpha Teknova?

Does the media refer more to NAUT or TKNO?

Which has more risk & volatility, NAUT or TKNO?

Is NAUT or TKNO more profitable?

Which has stronger earnings and valuation, NAUT or TKNO?

Do insiders and institutionals believe in NAUT or TKNO?

Do analysts recommend NAUT or TKNO?

Summary

How does Nautilus Biotechnology compare to Simulations Plus?

Do analysts rate NAUT or SLP?

Which has more volatility and risk, NAUT or SLP?

Does the media refer more to NAUT or SLP?

Which has better earnings & valuation, NAUT or SLP?

Is NAUT or SLP more profitable?

Do insiders & institutionals believe in NAUT or SLP?

Summary

How does Nautilus Biotechnology compare to Standard BioTools?

Which has higher earnings & valuation, NAUT or LAB?

Do analysts prefer NAUT or LAB?

Which has more risk & volatility, NAUT or LAB?

Does the media refer more to NAUT or LAB?

Do institutionals & insiders hold more shares of NAUT or LAB?

Is NAUT or LAB more profitable?

Summary

How does Nautilus Biotechnology compare to Codexis?

Is CDXS or NAUT more profitable?

Which has more volatility & risk, CDXS or NAUT?

Which has higher valuation and earnings, CDXS or NAUT?

Do analysts recommend CDXS or NAUT?

Do institutionals & insiders have more ownership in CDXS or NAUT?

Does the media prefer CDXS or NAUT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools